Abstract:Background: Episodic ataxias are rare neurological disorders characterized by recurring episodes of imbalance and coordination difficulties. Obtaining definitive molecular diagnoses poses challenges, as clinical presentation is highly heterogeneous, and literature on the underlying genetics is limited. While the advent of high-throughput sequencing technologies has significantly contributed to Mendelian disorders genetics, interpretation of variants of uncertain significance and other limitations inherent to individual methods still leaves many patients undiagnosed. This study aimed to investigate the utility of multi-omics for the identification and validation of molecular candidates in a cohort of complex cases of ataxia with episodic presentation. Methods: Eight patients lacking molecular diagnosis despite extensive clinical examination were recruited following standard genetic testing. Whole genome and RNA sequencing were performed on samples isolated from peripheral blood mononuclear cells. Integration of expression and splicing data facilitated genomic variants prioritization. Subsequently, long-read sequencing played a crucial role in the validation of those candidate variants. Results: Whole genome sequencing uncovered pathogenic variants in four genes ( SPG7 , ATXN2 , ELOVL4 , PMPCB ). A missense and a nonsense variant, both previously reported as likely pathogenic, configured in trans in individual #1 ( SPG7 : c.2228T>C/p.I743T, c.1861C>T/p.Q621*). An ATXN2 microsatellite expansion (CAG 32 ) in another late-onset case. In two separate individuals, intronic variants near splice sites ( ELOVL4 : c.541 + 5G>A; PMPCB : c.1154 + 5G>C) were predicted to induce loss-of-function splicing, but had never been reported as disease-causing. Long-read sequencing confirmed the compound heterozygous variants configuration, repeat expansion length, as well as splicing landscape for those pathogenic variants. A potential genetic modifier of the ATXN2 expansion was discovered in ZFYVE26 (c.3022C>T/p.R1008*). Conclusion: Despite failure to identify pathogenic variants through clinical genetic testing, the multi-omics approach enabled the molecular diagnosis in 50% of patients, also giving valuable insights for variant prioritization in remaining cases. The findings demonstrate the value of long-read sequencing for the validation of candidate variants in various scenarios. Our study demonstrates the effectiveness of leveraging complementary omics technologies to unravel the underlying genetics in patients with unresolved rare diseases such as ataxia. Molecular diagnoses not only hold significant promise in improving patient care management, but also alleviates the burden of diagnostic odysseys, more broadly enhancing quality of life.

Molecular diagnostic approach to rare neurological diseases from a clinician viewpoint

Next-generation sequencing and bioinformatics in rare movement disorders

Using Next-Generation Sequencing As A Genetic Diagnostic Tool in Rare Autosomal Recessive Neurologic Mendelian Disorders

Insights into Pathogenesis, Techniques for Variant Identification, and Therapeutic Approaches

The expanding diagnostic toolbox for rare genetic diseases

[Genetic testing in neurological diseases: a practical guide]

Long-read sequencing and optical genome mapping identify causative gene disruptions in noncoding sequence in two patients with neurologic disease and known chromosome abnormalities

Integration of multi-omics technologies for molecular diagnosis in ataxia patients

Application of next-generation sequencing technologies in Neurology.

Toward Clinical Implementation of Next-Generation Sequencing-Based Genetic Testing in Rare Diseases: Where Are We?

An update on the neurological short tandem repeat expansion disorders and the emergence of long-read sequencing diagnostics

Clinical exome sequencing in the diagnosis of pediatric neuromuscular disease

Diagnostic and Clinical Utility of Whole Genome Sequencing in a Cohort of Undiagnosed Chinese Families with Rare Diseases

Long-read genome sequencing and variant reanalysis increase diagnostic yield in neurodevelopmental disorders

Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: single-gene, gene panel, or exome/genome sequencing

Expanding the Boundaries of RNA Sequencing as a Diagnostic Tool for Rare Mendelian Disease

Beyond the exome: what's next in diagnostic testing for Mendelian conditions

Implementing genomic medicine in clinical practice for adults with undiagnosed rare diseases

Genome and RNA sequencing boost neuromuscular diagnoses to 62% from 34% with exome sequencing alone

Challenges and opportunities for discovering the biology of rare genetic diseases of the brain

“Genotype-First” Approaches on a Curious Case of Idiopathic Progressive Cognitive Decline